Plasma Volume expansion in cirrhosis - J of Hepatology - Jan.26

Introduction

Plasma volume expansion is a critical therapeutic strategy in the management of acute kidney injury (AKI) in patients with cirrhosis and ascites. AKI in cirrhosis often arises due to hypovolemia, which is frequently exacerbated by diuretic therapy, systemic vasodilation, and circulatory dysfunction inherent to advanced liver disease. The primary goal of plasma volume expansion is to restore effective circulating volume, improve renal perfusion, and mitigate kidney injury. Traditionally, therapeutic protocols have favored a fixed duration of plasma volume expansion, most commonly extending to forty-eight hours. However, evolving evidence and expert consensus have challenged this uniform approach, advocating for more individualized strategies tailored to patient response.

Problem Statement

Despite its central role in AKI management, plasma volume expansion presents several challenges:

1. Duration of Therapy: While a forty-eight-hour expansion period has historically been favored, recent discussions suggest shorter durations may suffice in certain cases. However, abbreviated protocols risk misclassifying AKI severity and prematurely discontinuing therapy in patients who may benefit from extended volume support.

2. Adverse Effects: Over-administration of fluids in non-responders can lead to complications, such as fluid overload, pulmonary edema, and worsening ascites. Conversely, insufficient resuscitation may fail to address hypovolemia, prolonging kidney injury and worsening outcomes.

3. Lack of Standardized Criteria: There is no universally accepted protocol regarding the type of fluid (e.g., albumin versus crystalloids), dosing, or criteria for assessing response. This lack of standardization complicates clinical decision-making and may lead to inconsistent practices across healthcare settings.

4. Identification of Non-Responders: Prolonged plasma volume expansion may be unnecessary in patients who fail to show early improvement, underscoring the importance of identifying non-responders and adapting therapy accordingly.

These challenges highlight the need for a more nuanced approach to plasma volume expansion, emphasizing individualized treatment strategies based on early assessment of therapeutic response.

Conclusion

Plasma volume expansion remains a cornerstone of AKI management in cirrhosis and ascites, but its application requires careful consideration to balance benefits against potential harms. While extending therapy to forty-eight hours may improve diagnostic accuracy in selected patients, it is vital to monitor response closely and reconsider prolonged fluid administration in non-responders. An individualized approach—guided by early assessment of therapeutic efficacy—offers the best opportunity to optimize outcomes while minimizing complications. Future research should focus on defining standardized criteria for fluid type, dose, duration, and response evaluation to refine plasma volume expansion strategies further.